Hyderabad-based Nucelion Therapeutics and Bengaluru's Pandorum Technologies have partnered to advance two PRIP-backed ophthalmology projects targeting advanced keratopathy and wet age-related macular degeneration. The projects have a combined planned outlay of Rs. 16.97 crore, including up to Rs. 8 crore in PRIP funding
Nucelion Therapeutics, a Bharat Biotech subsidiary, has partnered with VeGen Bio to manufacture VL-2511, a dual-target CAR-T therapy for multiple myeloma. The collaboration will focus on technology transfer, manufacturing scale-up and cost optimisation to support wider access in India.
Pandorum Technologies has partnered with Bharat Biotech arm Nucelion Therapeutics to expand manufacturing of its exosome-based regenerative therapies across the Asia-Pacific region, strengthening regional supply, regulatory readiness and India’s biologics manufacturing capabilities
